Director/PDMR Shareholding

RNS Number : 9713E

Epistem Holdings plc

04 January 2010

 



Epistem Holdings Plc ("Epistem" or the "Company")

Directors' Shareholdings

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009. 

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 258 ordinary shares of 1.5p each. These shares were acquired in tranches at the end of October, November and December at prices of 385p, 438p and 470p respectively.

The current beneficial interests of the executive Directors are set out below:

Matthew Walls	6,652	(0.08%)
Dr Catherine Booth	981,007	(12.36%)
Dr Ged Brady	1,007	(0.01%)
Dr Jeffrey Moore	15,507	(0.20%)
John Rylands	190,905	(2.41%)

For further details please contact:

Epistem Plc
Matthew Walls, CEO	[phone]
Piper Jaffray Ltd.
Neil Mackison / Rupert Winckler	[phone]

 

END

 

 

RDSBXGDBDSGBGGS